Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Determine the overall discriminatory ability of FET PET in the diagnosis of glioma grade II (referring to the current diagnostic gold standard represented by the histopathology exam of a tumor sample).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Toulouse

Criteria

Inclusion Criteria:

Patients over 18 years

• Diagnosis of glioma grade II referred on clinical and MRI morphologic

• Realization of a brain MRI in preoperative condition of neuronavigation (MRI sequences including axial T2, Flair, T1, T1 with gadolinium) in a within 1 month with FET PET.

• Histological examination scheduled within one month with FET PET by resection (complete or partial) or by biopsy

• Patients who signed informed consent

• No against-indication for PET

• No against-indications to MRI

Exclusion Criteria:

• Grade II glioma who have received specific treatment with radiotherapy and or chemotherapy.

• Pregnant or breastfeeding women.

• Weight greater than 120 Kg

• against-indication to PET

• against- indication gadolinium

• Possible side effects to MRI (magnetic foreign bodies, pacemaker, congestive severe renal).)

• Patient under guardianship

• No coverage by social security